Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,116 recruiting studies in this area right now.
By phase
- Not applicable9,488
- Phase 24,391
- Phase 12,658
- Phase 1/Phase 21,647
- Phase 31,391
- Phase 2/Phase 3281
- Phase 4260
Top conditions
- Breast Cancer1,192
- Prostate Cancer644
- Cancer632
- Colorectal Cancer478
- Lung Cancer415
- Ovarian Cancer336
- Multiple Myeloma328
- Pancreatic Cancer287
- Gastric Cancer283
- Acute Myeloid Leukemia279
- Hepatocellular Carcinoma256
- Solid Tumor245
- Advanced Solid Tumor235
- Head and Neck Cancer225
- Cervical Cancer223
- Endometrial Cancer206
- Advanced Solid Tumors199
- Esophageal Cancer189
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University303
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University273
- Mayo Clinic237
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences140
- City of Hope Medical Center140
- AstraZeneca134
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,404
- Texas636
- Arizona513
- Florida431
- Alabama424
- New York407
- Massachusetts340
- Maryland332
- New Jersey269
- Pennsylvania234
Recruiting studies20,116 total
- NCT06375161RecruitingEarly Phase 1
CAR-T cells for relapsed B-cell cancers
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
Shanghai, Shanghai MunicipalityAges 4 months–1.3 years - NCT05228431RecruitingPhase 2
Tested treatment plan for locally advanced rectal cancer
This Phase 2 study looks at a modified “sandwich” treatment sequence for people with locally advanced rectal cancer—aiming to control the cancer before and after surgery. It may help you if you’re eligible and can follow the study’s treatment and safety requirements.
Guangzhou, GuangdongAges 18–75 - NCT06252298RecruitingPhase 1
Testing a new drug for CD38-positive blood cancers
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06260410Recruiting
Lu-PSMA prostate cancer data study
This study collects information (like scans and blood tests) from men with prostate cancer who are about to start Lu-PSMA therapy. The goal is to track how the cancer responds and learn more about its features during treatment.
Rotterdam, South HollandAges 18 years+ - NCT06360042RecruitingPhase 2
Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+ - NCT06378892RecruitingPhase 2
Study of chemo plus lorlatinib for ALK+ lung cancer
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
AvianoAges 18 years+ - NCT06380387Recruiting
Metabolism in children before and after brain tumor treatment
This study looks at how the body's energy use (metabolism) changes in children with a brain tumor before and after treatment. The goal is to understand how the tumor and its treatment affect the body, which may help improve care in the future.
Copenhagen, Copenhagen ØAges 6–18 - NCT06369181Recruiting
Study on cell changes in lung cancer with RB1/TP53 gene changes
This trial looks at what happens when certain types of non-small cell lung cancer—those with changes in the RB1 and TP53 genes—start to change into another type of lung cancer after treatment. It may help find better ways to treat this specific kind of cancer in the future.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02265770RecruitingPhase 2/Phase 3
Treatment plan for children with brain ependymoma after surgery
This trial tests different follow-up treatments for children with brain ependymoma after their initial surgery. Which treatment you get depends on how much tumor is left (if any) and whether the child can safely receive radiation and chemotherapy.
GrazAges Up to 22 years - NCT03659448RecruitingPhase 3
Test drug that helps map colon and rectal cancer during surgery
This Phase 3 study tests SGM-101, a drug used during surgery to help doctors better outline primary, recurrent, and spread (metastatic) colorectal cancer. It may improve how completely tumors are identified and removed during an operation.
Duarte, CaliforniaAges 18 years+ - NCT03767075RecruitingPhase 2
Basket trial matching cancer patients to targeted treatments
This trial tests whether matching your tumor’s DNA/RNA results to a specific cancer medicine can work better than standard options when cancer has spread or can’t be removed by surgery. You may be assigned to a “basket” (sub-study) based on the exact changes found in your tumor.
VillejuifAges 18 years+ - NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT06257030Recruiting
Liver tumor treatment study for large tumors
This study tests a targeted radiation treatment called Y90 for liver tumors that are too large for standard approaches. It aims to see how well the treatment works for people with primary or secondary liver cancers that mainly affect the liver and have at least one tumor bigger than 5 cm.
Pátrai, AchaiaAges 18 years+ - NCT06256224Recruiting
Toripalimab with standard chemoradiation for advanced cervical cancer
This trial combines the immunotherapy drug toripalimab with standard chemoradiation to treat newly diagnosed advanced cervical cancer. It aims to see if adding toripalimab improves outcomes for patients whose cancer has not spread to distant organs.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06381726Recruiting
Personalized brain mapping to protect movement during glioma surgery
This study tests a personalized approach to map and protect the brain's movement pathways during surgery for slow-growing brain tumors. The goal is to remove as much tumor as possible while keeping your quality of life and movement abilities intact.
Milan, LombardyAges 18 years+ - NCT03685890RecruitingPhase 1/Phase 2
Testing nivolumab for melanoma spread to the limb skin
This trial studies nivolumab, an immune medicine, for melanoma that has spread to the skin along a limb (called in-transit metastases). It’s given after a procedure that delivers higher treatment levels to the affected limb, with the goal of shrinking the melanoma and improving outcomes.
AmsterdamAges 18 years+ - NCT05909241RecruitingPhase 1
First study of BA1202 for advanced solid tumors
This Phase 1 study tests BA1202 in people with advanced solid cancers to find safe dosing and how the treatment may work. You may qualify if your cancer has progressed or you cannot use standard treatment, and—depending on the group—your tumor shows a specific marker called CEACAM5.
BeijingAges 18–70 - NCT06361043Recruiting
Adaptive radiation therapy for esophageal cancer
This study tests a new, more precise type of radiation therapy for esophageal cancer that adjusts the treatment in real time using a special CT scan. It aims to deliver a stronger dose to the tumor while sparing healthy tissue, which could improve outcomes.
BernAges 18 years+ - NCT03749980Recruiting
Study following people with von Hippel-Lindau (VHL)
This study follows people who have von Hippel-Lindau (VHL) over time to better understand how the condition changes. It may help doctors plan future treatments by collecting long-term health information.
Boston, MassachusettsAges Any age - NCT06385990RecruitingPhase 2
Utidelone plus Capecitabine for residual triple-negative breast cancer
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
Changsha, HunanAges 18–70 - NCT05345587Recruiting
Digital monitoring plus proactive medication review during oral cancer treatment
This trial tests whether combining regular medication safety checks with electronic tracking of side effects can improve quality of life and help reduce economic burden for people taking cancer pills. It’s for people starting oral cancer therapy and using connected technology to report symptoms.
Brive-la-GaillardeAges 18 years+ - NCT06387017Recruiting
Can blood tests improve lung cancer screening in smokers with artery disease?
This study looks at whether certain blood tests can help find lung cancer early in people who have smoked for a long time and also have artery disease. The goal is to see if adding these tests to current screening methods can better identify those at highest risk.
MarseilleAges 45–80 - NCT06300177RecruitingPhase 3
New targeted pill vs. chemotherapy for KRAS G12C lung cancer
This trial compares a new targeted pill (D-1553) against a standard chemotherapy (docetaxel) for people with a specific type of advanced lung cancer (KRAS G12C mutation) whose cancer has stopped responding to first-line immunotherapy and chemotherapy.
Hefei, AnhuiAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,116 recruiting oncology studies from the U.S. registry right now, out of 29,780 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.